Shares in Imricor Medical Systems Inc (ASX: IMR) have been on the slide recently, falling from levels above $2 to just $1.56 at the time of writing.

This has created a buying opportunity, according to the analysts at Morgans, who have issued a new research report into the company with a bullish share price target.

Innovative medical technology gaining traction

Imricor has developed a suite of products such as catheters, sheaths, and other tools which can be used under real-time magnetic resonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR’s superior imaging capabilities.

The company has had some wins recently, with the Children’s Medical Centre Dallas signing up to buy Imricor’s NorthStar mapping and guidance system, becoming the second US hospital customer just two weeks after the launch of the company’s US commercial operations.

Imricor said:

Children’s Medical Center Dallas will be the second customer under Imricor Cardiovascular, validating the newly launched vertical and the market opportunity across more than 250 children’s hospitals and more than 2,000 adult hospitals in the United States.

The company also recently announced that the US Food and Drug Administration had approved a manufacturing module which covers the design, manufacturing, and quality processes around seven Imricor products.

Imricor Chair Steve Wedan said:

Manufacturing is one of the most demanding components of any PMA, and ours covered seven devices at once. To have the FDA complete its evaluation and close this module is a strong validation of the design controls, production processes and quality system our team has built. It is the kind of milestone that is easy to state in a sentence but very hard to earn.

Morgans said in its new research note on the company that its share price had fallen more than 20% since it entered the S&P/ASX 300 Index (ASX: XKO).

The broker added:

The recent share price weakness creates a great buying opportunity. The recent news flow has been positive and we expect further key milestones to be announced over the next three to six months.

Morgans said a collaboration with Philips combining Philips’ MRI platform with Imricor’s cardiac systems and catheters offered a purpose-built alternative to x-ray guidance.

They added:

It is available immediately in CE-marked (European) markets. The partnership expands IMR’s commercial reach and creates a scalable platform for future MRI-guided interventions across additional clinical application. We expect this will accelerate commercial adoption across the Philips global network. The other major manufacturers (Siemens and GE Health) will be following suit.

Morgans has a price target of $2.90 on Imricor shares compared to $1.56 at the time of writing, which would represent upside of 85.9%.

Imricor is valued at $568.3 million.

The post Could this ASX biotech really jump more than 80% in value? appeared first on The Motley Fool Australia.

More reading

• By October 2027, $5,000 invested in Xero shares could turn into…
• Buy, hold, sell: Aristocrat, Liontown, and Navigator Global shares
• This ASX 200 share is tipped to return over 50%
• Stockland vs Vicinity Centres: Which ASX REIT is the better buy?
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended GE HealthCare Technologies. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Xero Ltd (ASX: XRO) shares fell further into the red in September, down around 31% over the course of the month.

At the time of writing, the ASX technology stock is down around 1% to $57.39. That means the shares are down 49% year-to-date and 64% lower than 12 months ago.

It’s been well-documented that the cloud-based accounting software business has been smashed by a tech-sector wide selloff this year after investors became spooked that AI could replace the core services of companies like Xero. 

There has also been an investor rotation away from growth stocks and into more defensive assets amid ongoing global volatility and inflation concerns.

No price-sensitive news explains why Xero shares have shed so much value over the past month. Investors may have taken profits after the shares rebounded strongly through July and most of August.

The resurgence of macroeconomic pressures has also spooked investors across the board. This hasn’t helped Xero’s share price downturn.

Concerns about the latest inflation figures and the Reserve Bank’s interest rate hike in September has only contributed to headwinds.

The Reserve Bank raised the cash rate to a 15-year high of 4.6% at its meeting earlier this week. On Wednesday, the Australian Bureau of Statistics (ABS) announced that Australia’s annual headline inflation rate jumped to 4% in the 12 months to August 2026, up from 3.5% the month prior.

As of late September, Australian 10-year bond yields were sitting at around 5.36%, which hasn’t helped high-growth tech stocks either.

The question now is, are Xero shares still a buy? Or will any investment made today turn into a loss by October 2027?

What’s ahead for Xero?

The company has sticky subscription revenue, and I see huge potential for growth both into new markets and with new offerings.

It looks like the experts are also bullish on Xero shares.

Market Index data shows that most brokers rate the shares a buy. The $112 average target price implies that the shares could jump another 95%, at the time of writing.

Sentiment is also very positive on TradingView. Out of seven analysts, six have a buy/strong buy rating and one rates the shares as a hold. However, they all agree there will be upside ahead.

The average $113.31 target price implies a potential 97% upside, while the maximum $144.36 implies Xero’s shares could rise by another 151% at the time of writing.

If I buy $5,000 of Xero shares today, what could they be worth in 12 months time?

Assuming Xero shares reach the average forecasted target prices of $112 or $113.31, a $5,000 investment today could be worth around $9,750 or $9,850 by October 2027.

However, if the more bullish expert forecasts come to fruition, a $5,000 investment today could grow to $12,550 by this time next year.

The post By October 2027, $5,000 invested in Xero shares could turn into… appeared first on The Motley Fool Australia.

More reading

• Codan vs Xero: Which ASX tech stock is the better buy in October?
• 5 leading ASX shares I’d buy and hold until 2040
• Buy, hold, sell: Premier Investments, New Hope, Xero shares
• Can the Xero share price climb back to $100?
• Sell alert! Why this expert is calling time on Life360 and Xero shares

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Morgans has been busy running the rule over a number of ASX shares this week.

But does the broker rate them as buys? Let’s see what it is recommending:

Aristocrat Leisure Ltd (ASX: ALL)

Morgans has made minor revisions to its estimates ahead of this gaming technology company’s results next month.

However, it remains very positive and has retained its accumulate rating on Aristocrat Leisure’s shares with a slightly trimmed price target of $69.00. This implies potential upside of approximately 17% for investors. It said:

With G2E in Las Vegas this week, and ahead of its FY26 result on 12 November, we have made minor revisions to our earnings forecasts. We lower our FY26-27 fee per day and North American outright unit forecasts and our FY26 Product Madness bookings. We also lift our AUD/USD assumption and increase our buy-back assumptions. 

Our NPATA forecasts fall by c.1% across FY26-27F. EPSA is broadly unchanged in FY26 and up c.1% in FY27, reflecting higher buy-backs. Our 12-month target price decreases to A$69.00 (prev. A$70.00). We maintain our Accumulate recommendation.

Liontown Ltd (ASX: LTR)

Another ASX share that Morgans has been looking at is lithium miner Liontown.

In response to its production expansion announcement, the broker has retained its accumulate rating with a $1.10 price target. This suggests that upside of almost 40% is possible for investors. It commented:

LTR has approved the A$389m Kathleen Valley Expansion, targeting ~780ktpa of spodumene concentrate from FY30, with steady-state production in line with our expectations but unit costs above MorgansF and consensus. 

Our target price falls to A$1.10ps (from A$1.40ps) on a slower FY28-FY29 ramp-up and higher near-term capex and costs, with falling lithium prices and execution now the key risks. We maintain our ACCUMULATE rating with a A$1.10ps target price.

Navigator Global Investments Ltd (ASX: NGI)

This global investment company’s shares could be worth considering according to Morgans.

In response to news that Navigator Global is selling its stake in Invictus Capital Partners, the broker has retained its buy rating with a $3.04 price target. This implies potential upside of 27% for investors from current levels. It said:

NGI has agreed to sell its stake (21%) in Invictus Capital Partners to New York Life Investment Management (NYLIM). The sale will take place in several stages. The sale crystallises a premium of up to ~8% to cost on the initial 12.7% stake, while NGI keeps its carry and future upside through a residual 8.3% stake. Management expects the retained stake could be worth meaningfully more, on a pro-rata basis, when it is transferred in 2031, helped by the NYLIM partnership. 

In our view, the sale shows the optionality and embedded value in NGI’s portfolio. We have left our earnings forecasts unchanged for now and will wait for more detail from NGI at its February result. That timing matches the expected transaction completion in the first quarter of 2027. We see long-term value in the NGI story and maintain our BUY recommendation and target price of A$3.04.

The post Buy, hold, sell: Aristocrat, Liontown, and Navigator Global shares appeared first on The Motley Fool Australia.

More reading

• Forget PLS, this ASX lithium stock could rise 80%
• 5 things to watch on the ASX 200 on Thursday
• Barrenjoey tips this ASX financial stock to rise 73%
• Liontown Resources approves $389m Kathleen Valley lithium expansion
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.